EIF2A and prostate cancer: Apart from directly inhibiting PERK signaling, ISRIB is a potent eIF2α inhibitor, which significantly inhibits the progression of prostate cancer by blocking the phosphorylation signaling of eIF2α (Nguyen et al., 2018).